Cart
sales@molnova.com
GFT505
CAS No. 824932-88-9
GFT505( Elafibranor )
Catalog No. M28578 CAS No. 824932-88-9
GFT505 (Elafibranor) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 49 | In Stock |
|
| 2MG | 30 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 106 | In Stock |
|
| 50MG | 173 | In Stock |
|
| 100MG | 267 | In Stock |
|
| 200MG | 401 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGFT505
-
NoteResearch use only, not for human use.
-
Brief DescriptionGFT505 (Elafibranor) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
-
DescriptionGFT505 (Elafibranor) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
-
In Vitro——
-
In Vivo——
-
SynonymsElafibranor
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number824932-88-9
-
Formula Weight384.49
-
Molecular FormulaC22H24O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)(C(O)=O)Oc1c(C)cc(C=CC(c(cc2)ccc2SC)=O)cc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Todd JS, Gerwick WH. Isolation of a cyclic carbonate, a gamma-butyrolactone, and a new indole derivative from the marine cyanobacterium Lyngbya majuscula. J Nat Prod. 1995 Apr;58(4):586-9.
molnova catalog
related products
-
L-165041
L-165041 is a potent and selective agonist of the nuclear receptor PPARβ and PPARδ(Ki = 9 nM EC50 = ~500 nM respectively).
-
Daltroban
Daltroban (SKF 96148) is a specific thromboxane A2 (TXA2) receptor antagonist. Daltroban shows protective effect in reperfusion injury. Daltroban increase intracellular calcium in vascular smooth muscle cells.
-
Saroglitazar
A novel PPAR agonist with predominant PPARα and moderate PPARγ activity with EC50 of 0.65 pM and 3 nM respectively.
